In This Episode We Discuss: Treatments for Neurological and Psychiatric Conditions
What you’ll get out of this episode:
- Revolutionizing Treatments: Dr. Sam Clark discusses Terran Biosciences’ mission to innovate treatments for neurological and psychiatric conditions.
- Innovative Drug Development: The company focuses on creating new mechanisms for treating depression, bipolar disorder, and schizophrenia.
- Smaller, Agile Teams: Terran Biosciences operates with a flat structure, utilizing highly trained experts to solve complex problems.
- Addressing Patent Monopolies: The company aims to break patent monopolies in pharma through innovative approaches and pro-drug strategies.
- Exciting Developments: Dr. Clark teases upcoming announcements, including long-acting and improved drug forms.
Watch
Listen
Read More on Treatments for Neurological and Psychiatric Conditions
Introduction
In this episode of the Bio Breakthroughs podcast, Jared Taylor interviews Dr. Sam Clark, CEO and Founder of Terran Biosciences. The conversation delves into the company’s mission, innovative treatments for neurological and psychiatric conditions, and exciting future developments.
Revolutionizing Neuropsychopharmacology Treatments
Dr. Clark founded Terran Biosciences to address the gaps in treatment for neurological and psychiatric conditions. He emphasizes the need for new mechanisms, stating, “The current treatments leave a lot to be desired.” The company focuses on developing novel approaches for conditions like depression, bipolar disorder, and schizophrenia, moving away from outdated treatments such as SSRIs and antipsychotics.
Innovative Drug Development and Pro-Drug Strategies
Terran Biosciences is known for its innovative drug development approach, particularly focusing on drugs with human data already available. Dr. Clark highlights the success story of idaxoxan, a drug for treating schizophrenia that the company transformed from a four-times-a-day medication to a once-daily formulation. The company also leverages pro-drug strategies to improve drug forms, making them more effective and accessible.
Building a Collaborative and Agile Team
Dr. Clark emphasizes Terran Biosciences’ unique team structure, inspired by Silicon Valley’s fast-moving companies. The company operates with a flat structure, allowing highly trained experts to tackle specific problems collaboratively. This agile approach has contributed to their success in developing new treatments and breaking through industry barriers.
Addressing Patent Monopolies
Terran Biosciences aims to address patent monopolies in the pharmaceutical industry. While the company supports patents for innovation, Dr. Clark highlights the issue of patent system abuse, particularly when secondary patents are used to extend drug monopolies. The company focuses on developing improved drug forms and utilizing the FDA’s 505(b)(2) pathway to bring affordable and effective medications to patients quickly.
Exciting Developments and Future Outlook
Dr. Clark shares exciting future developments for Terran Biosciences, including the potential of idaxoxan for treating schizophrenia and new forms of psychedelics for rapid treatment development. The company is also working on new pro-drug programs to improve existing neuroscience drugs. Dr. Clark looks forward to unveiling these developments at upcoming conferences, including Bio, ECNP, and ACNP.
WORD FROM OUR SPONSORS:
Our sponsor for this episode are Sage Growth Partners.
Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media – @sagegrowthpartners
To learn more about our guest and their innovative addiction treatments:
– Guest’s LinkedIn – Company LinkedIn – Website –
Also, be sure to follow Slice of Healthcare on our social channels:
– Website – LinkedIn – Twitter – YouTube – Newsletter –
